VICTORIA Trial of Vericiguat for Worsening HF Meets Primary Endpoint

Nov 20, 2019 | TCTMD Articles

The phase III VICTORIA trial of vericiguat, an investigational drug for patients worsening chronic heart failure and reduced ejection fraction, met its primary endpoint, drugmakers Merck and Bayer AG announced on Monday.

X